Genmab Reaches USD 10 Million Milestone in Daratumumab Collaboration with Janssen

Milestone triggered by progress in the Phase III study of daratumumab in combination with bortezomib and dexamethasone

28-Oct-2014 - Denmark

Genmab A/S announced it has reached the fourth milestone in its daratumumab collaboration with Janssen Biotech, Inc.. The USD 10 million milestone payment was triggered by progress in the ongoing Phase III study (“CASTOR” MMY3004) of daratumumab in combination with bortezomib and dexamethasone compared to bortezomib and dexamethasone alone for the treatment of relapsed or refractory multiple myeloma.

“We are very pleased with the firm progress being made in the daratumumab development program under the direction of our strategic partner Janssen. At Genmab we are committed to developing differentiated therapeutics to fight cancer, and it is therefore rewarding to see one of our antibodies moving rapidly through clinical development,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

Other news from the department research and development

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?